Lyra therapeutics reports second quarter 2024 financial results and provides corporate update

– primary focus continues to be on upcoming results from enlighten 1 phase 3 extension study in 4q 2024 and enlighten 2 pivotal phase 3 trial in crs patients in 1h 2025, as planned –

LYRA Ratings Summary

LYRA Quant Ranking